+91 8617752708

British Journal of Pharmaceutical Research, ISSN: 2231-2919,Vol.: 14, Issue.: 4

Original-research-article

Development and Validation of Bio Analytical Method for Estimation of Bortezomib in k3 EDTA Human Plasma Using HPLC-ESI-MS/MS and Its Application to a Bioequivalence & CME Studies

 

Ravi Pratap Pulla1*, K. Vanitha Prakash1, U. B. Abhini1, B. Naga Maheswari1, V. Divya1, M. V. Shushmitha1 and V. Ravali1

1SSJ College of Pharmacy, V. N. Pally, Gandipet, Hyderabad-75, Telangana State, India.

Article Information
Editor(s):
(1) Rahul S. Khupse, Pharmaceutical Sciences, University of Findlay, USA.
Reviewers:
(1) Marina Quartu, University of Cagliari, Italy.
(2) Tommasina Guglielmelli, San Luigi Hospital, Italy.
Complete Peer review History: http://www.sciencedomain.org/review-history/17605

Abstracts

Purpose: To develop a highly selective, reproducible & precise rugged bio analytical method for estimation of Bortezomib (BTZ), “A Protease Inhibitor” in human plasma by validating the developed method in accordance to US-FDA guidelines.

Methodology Envisaged: BTZ D3 was used as an internal standard (ISTD) for the determination of BTZ in human plasma using a rapid & specific liquid chromatographic – Electron Spray Ionization –Mass spectrometric method. The analytical method was moduled with liquid-liquid phase extraction by using annular centrifugal contactor & the samples were analyzed by HPLC, on a column - ACE 5CN (150 x 4.6 mm 5 µm), using mobile phase consisting of ammonium formate buffer: ACN (25:75 v/v), delivered at 1.0 ml/min & 90% flow spitting. Applied Bio system MDS Sciex API 3000 Triple Quadruple MS equipped with Turbo Ion Spray (TIS) as LC/MS interface was used in for MS detection. TIS with multiple reaction monitoring (MRM) were acquired by ESI mass spectra, using the transitions m/z 362.95→310.21 & m/z 172.64→146.06 to quantify BTZ & BTZ D3 respectively.

Results: % variability was ≤ 5.52 & ≤ 6.15 [that was ≤ 15], indicating the specificity of the method, showing no matrix interferences across the elution system. Acceptance is ranging between -8.30 to 2.83 & -4.32 to 1.00% (< 5% CV) & accuracy in the range of 92.73 – 102.20 (< 10% difference) was observed over a linear range of 2.00 – 1000 ng/mL. The mean (n=3) correlation coefficient was 0.9991 & overall mean recovery was 85.62%. Retention time for drug & ISTD is found out to be 0.08 & 0.07; % CV of area ratio is 1.91% & area ratio ≤ 2.51%, which indicated system suitability.

Interpretation and Conclusion: The intended analyte is stable below 10ºC in all the performed stability experimentation & within the acceptance limits. It can be used for investigating drug concentration in routine quality control analysis in API & its pharmaceutical dosage forms.

Keywords :

Bortezomib; Bortezomib D3; method validation; HPLC-ESI-MS/MS; human plasma; multiple reaction monitoring.

Full Article - PDF    Page 1-17

DOI : 10.9734/BJPR/2016/30565

Review History    Comments

Our Contacts

Guest House Road, Street no - 1/6,
Hooghly, West Bengal,
India

+91 8617752708

 

Third Floor, 207 Regent Street
London, W1B 3HH,
UK

+44 20-3031-1429